{"url_path":"/sec/atrc/8-k/2026-05-19/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1323885/0001323885-26-000025-index.html","accession_number":"0001323885-26-000025","cik":"0001323885","ticker":"ATRC","issuer_name":"AtriCure, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1323885/0001323885-26-000025-index.html","primary_entity_key":"0001323885","primary_entity_name":"AtriCure, Inc."},"word_count":381,"has_tables":true,"body_markdown":"Item 5.07.    Submission of Matters to a Vote of Security Holders.\n\nThe stockholders of the Company voted on the following proposals at the Annual Meeting:\n\n1.The election of nine directors to serve one-year terms expiring at the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;\n\n2.A proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;\n\n3.The approval of an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,500,000;\n\n4.The approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized by 750,000; and\n\n5.An advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement.\n\nFor more information about the five proposals that were voted on at the Annual Meeting, see the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on April 6, 2026.\n\nThe voting results for each of the proposals are as follows:\n\n1. All nominees for director were duly elected to serve one-year terms expiring at the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.\n\nDirector NomineesForAgainstAbstainBroker Non-Votes\n\nMichael H. Carrel41,848,141264,29768,7103,820,943\n\nRegina E. Groves41,852,934258,66269,5523,820,943\n\nB. Kristine Johnson41,685,893426,14969,1063,820,943\n\nShlomo Nachman41,846,048260,88974,2113,820,943\n\nKaren N. Prange41,514,921590,76375,4643,820,943\n\nDeborah H. Telman40,917,9731,192,57370,6023,820,943\n\nSven A. Wehrwein41,454,342653,54273,2643,820,943\n\nRobert S. White41,025,7951,086,03269,3213,820,943\n\nMaggie Yuen41,447,687663,91469,5473,820,943\n\n2. The stockholders approved the proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nFor:43,617,566 \n\nAgainst:2,327,505 \n\nAbstain:57,020 \n\n3. The stockholders approved the amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,500,000.\n\nFor:41,051,336 \n\nAgainst:1,066,332 \n\nAbstain:63,480 \n\nBroker Non-Votes:3,820,943 \n\n4. The stockholders approved the amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized by 750,000.\n\nFor:42,064,798 \n\nAgainst:109,893 \n\nAbstain:6,457 \n\nBroker Non-Votes:3,820,943 \n\n5. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.\n\nFor:40,373,427 \n\nAgainst:1,745,379 \n\nAbstain:62,342 \n\nBroker Non-Votes:3,820,943"}